TheraCryf Advances Ox-1 Program Amidst Addiction Awareness Week

Evgen Pharma ( (GB:TCF) ) has provided an update.

TheraCryf plc announced its support for Addiction Awareness Week 2025, highlighting the significant unmet medical needs in addiction treatment. The company is advancing its Ox-1 orexin-1 blocker program, targeting binge eating disorder and substance use disorders, with manufacturing progressing ahead of schedule and robust patent protection secured. The initiative aims to address the high human and economic costs associated with addiction, with clinic readiness expected by the end of 2026.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focusing on brain disorders, with a diverse pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data to advance its clinical programs and partner with larger pharmaceutical companies for trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire, trading on AIM under the ticker TCF.

Average Trading Volume: 4,333,346

Technical Sentiment Signal: Sell

Current Market Cap: £4.08M

For a thorough assessment of TCF stock, go to TipRanks’ Stock Analysis page.